BBH

Featured

HOLDRS Making Transition to Market Vector ETFs

By Tom LydonNovember 23, 2011

New ETFs

Van Eck, Merrill Lynch in Agreement Over HOLDRS

By Tom LydonAugust 15, 2011

Featured

Biotech ETFs Mixed After Gilead Subpoena

By Tom LydonJune 13, 2011

Featured

Biogen Earnings, Drug Data to Lift Biotech ETFs

By John SpenceApril 21, 2011

Featured

5 Biotechnology ETFs to Play Innovation

By Tom LydonFebruary 22, 2011

Featured

Play the Booming Biotech Sector With ETFs

By Tom LydonDecember 21, 2010

Featured

Biotech ETFs: 5 Ways to Play Innovation

By Tom LydonAugust 8, 2010

Featured

5 Biotech ETFs If You’re Bullish

By Tom LydonJune 25, 2010

Featured

Why Biotech ETFs May Be the Better Choice

By Tom LydonJune 17, 2009

Featured

How Biotech ETFs Can Rise Above Challenges

By Tom LydonMay 12, 2009

Featured

How Biotech ETFs Are Overcoming Sector’s Trials

By Tom LydonMarch 24, 2009

Featured

Midday Market Update: Downgrades and Mergers Lead Markets and ETFs

By Tom LydonMarch 12, 2009

Featured

What Stem Cell Research Means for Biotech ETFs

By Tom LydonMarch 10, 2009

Featured

How Obama’s Health Care Reform Impacts Biotech ETFs

By Tom LydonMarch 5, 2009

Featured

Midday Market Update: Can New Program Spark an ETF Rally?

By Tom LydonMarch 3, 2009

Featured

Health Care ETFs’ $140 Billion Boost

By Tom LydonFebruary 19, 2009

Featured

Why Biotech, ETFs Want Piece of Bailout

By Tom LydonDecember 11, 2008

Featured

Biotech ETFs Stay Healthy Despite Market Ills

By Tom LydonOctober 22, 2008